Team:Georgia State/Oursystem

From 2010.igem.org

Latest revision as of 03:21, 28 October 2010

• Home
• Project
  • About The Toolkit
  • Oursystem
  • Producing The Antigen
  • Future Applications
  • Safety
• Toolkit
• Why Pichia
  • Pichia Vs Saccharomyces
  • Easy and Inexpensive to Culture
  • High production of foreign Protein while low levels of endogenous protein
  • Pichia pastoris versus Esherichia coli
• Protocols
  • Preparation Of Electrocompetent Cells
  • Preparation of Heat Shock Competent Cells
  • Transformation Using Electroporation
  • Transformation Using Heat Shock
• The Team
• Notebook

H1N1 VACCINE

Background: In 2009 the World Health Organization raised its pandemic alert for H1N1 influenza A virus to the 6 phase alert. This is the highest alert level and it indicates widespread community transmission of the virus in over two continents. The H1N1 Influenza A virus is a quadruple reassortment of two swine strains, one human strain, and one avian strain. More than 214 countries and territories have reported laboratory – confirmed cases of pandemic H1N1 Influenza A. The US Centers for Disease Control and Prevention reported between April 2009 and April 2010, approximately 61million cases of pandemic H1N1 occurred, including 274,000 hospitalizations and 12,470 deaths.

Problem: Efficient and timely vaccine production was a challenge for the scientific community during the pandemic outbreak of H1N1. Another problem with the Influenza viruses is the high variability and mutations that they present with each year. This makes vaccine production time difficult and time consuming.

The Pichia System: The Pichia system is an ideal construct for producing vaccines. We have designed a standard Pichia system that can be used for the production of various different vaccines. In theory, a high yield circuit can be established that only requires the exchange of the variable antigen, while leaving the remaining factors constant. In the circuit presented below, a vector has been designed to express the HA globular head influenza A antigen under the control of the strong constitutive promter pGAP.